269 related articles for article (PubMed ID: 36999711)
21. Clinical pharmacology of dopamine agonists in Parkinson's disease.
Lange KW
Drugs Aging; 1998 Nov; 13(5):381-9. PubMed ID: 9829165
[TBL] [Abstract][Full Text] [Related]
22. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
Markham A; Benfield P
CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
[TBL] [Abstract][Full Text] [Related]
23. New dopaminergic therapies for PD motor complications.
Larson D; Simuni T
Neuropharmacology; 2022 Feb; 204():108869. PubMed ID: 34742740
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.
Nyholm D
Clin Pharmacokinet; 2006; 45(2):109-36. PubMed ID: 16485914
[TBL] [Abstract][Full Text] [Related]
25. Potential therapeutic use of the selective dopamine D1 receptor agonist, A-86929: an acute study in parkinsonian levodopa-primed monkeys.
Grondin R; Bédard PJ; Britton DR; Shiosaki K
Neurology; 1997 Aug; 49(2):421-6. PubMed ID: 9270571
[TBL] [Abstract][Full Text] [Related]
26. The rationale for the use of dopamine agonists in Parkinson's disease.
Jenner P
Neurology; 1995 Mar; 45(3 Suppl 3):S6-12. PubMed ID: 7715795
[TBL] [Abstract][Full Text] [Related]
27. Early Parkinson's disease: what is the best approach to treatment.
Hristova AH; Koller WC
Drugs Aging; 2000 Sep; 17(3):165-81. PubMed ID: 11043817
[TBL] [Abstract][Full Text] [Related]
28. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
Chase TN
Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
[TBL] [Abstract][Full Text] [Related]
29. Dopamine agonist therapy in early Parkinson's disease.
Stowe RL; Ives NJ; Clarke C; van Hilten J; Ferreira J; Hawker RJ; Shah L; Wheatley K; Gray R
Cochrane Database Syst Rev; 2008 Apr; (2):CD006564. PubMed ID: 18425954
[TBL] [Abstract][Full Text] [Related]
30. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
Parkinson Study Group
JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
[TBL] [Abstract][Full Text] [Related]
31. Markers for dopaminergic neurotransmission in the cerebellum in normal individuals and patients with Parkinson's disease examined by RT-PCR.
Hurley MJ; Mash DC; Jenner P
Eur J Neurosci; 2003 Nov; 18(9):2668-72. PubMed ID: 14622169
[TBL] [Abstract][Full Text] [Related]
32. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
[TBL] [Abstract][Full Text] [Related]
33. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
34. Early introduction of dopamine agonists in the long-term treatment of Parkinson's disease.
Ogawa N
Neurology; 1998 Aug; 51(2 Suppl 2):S13-20. PubMed ID: 9711975
[TBL] [Abstract][Full Text] [Related]
35. The 'magic' of L-dopa: why is it the gold standard Parkinson's disease therapy?
Mercuri NB; Bernardi G
Trends Pharmacol Sci; 2005 Jul; 26(7):341-4. PubMed ID: 15936832
[TBL] [Abstract][Full Text] [Related]
36. Dinapsoline: characterization of a D1 dopamine receptor agonist in a rat model of Parkinson's disease.
Gulwadi AG; Korpinen CD; Mailman RB; Nichols DE; Sit SY; Taber MT
J Pharmacol Exp Ther; 2001 Feb; 296(2):338-44. PubMed ID: 11160615
[TBL] [Abstract][Full Text] [Related]
37. Dopamine D
Lewis MM; Van Scoy LJ; De Jesus S; Hakun JG; Eslinger PJ; Fernandez-Mendoza J; Kong L; Yang Y; Snyder BL; Loktionova N; Duvvuri S; Gray DL; Huang X; Mailman RB
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238699
[TBL] [Abstract][Full Text] [Related]
38. Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.
Mishra A; Singh S; Tiwari V; Bano S; Shukla S
Behav Brain Res; 2020 Jan; 378():112304. PubMed ID: 31626851
[TBL] [Abstract][Full Text] [Related]
39. [Are dopamine agonists alternative therapy for levodopa in early stage of Parkinson's disease? Yes].
Szczudlik A; Rudzińska M
Neurol Neurochir Pol; 2007; 41(2 Suppl 1):S6-9. PubMed ID: 17941452
[TBL] [Abstract][Full Text] [Related]
40. Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease.
Calne DB
J Neural Transm Suppl; 1999; 56():185-92. PubMed ID: 10370912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
